Trinity Biotech Plc Sponsored ADR Class A Aktie News

Trinity Biotech plc (NASDAQ:TRIB ) Q1 2024 Results Conference Call May 23, 2024 8:30 AM ET Company Participants Eric Ribner - Investor Relations John Gillard - Chief Executive Officer Des Fitzgerald - Chief Financial Officer Conference Call Participants Jim Sidoti - Sidoti & Company Operator Greetings, and welcome to the Trinity Biotech First Quarter 2024 Earnings Call. [Operator Instructions] ...

-Business performance on track to achieve approximately $20 million of annualized run-rate EBITDASO 1 on annualized revenues of approximately $75 million by Q2 2025-

DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, will report financial results for the first quarter 2024 on Thursday, May 23, 2024 at 8:30 AM ET. Conference Call Dial-In & Webcast Information Date: Thursday,...

DUBLIN, Ireland, May 16, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic collaboration with medical artificial intelligence (“AI”) company PulseAI to enhance the Company's recently acquired continuous glucose monitor (CGM...

DUBLIN, Ireland, May 13, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received substantial additional orders for TrinScreen HIV, bringing total orders received to date for supply in 2024 to approximately $6 million.

DUBLIN, Ireland, May 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Avinash Kale as Continuous Glucose Monitor (CGM) Programme Director. His appointment is a critical step forward in advancing the Company's re...

Trinity Biotech plc (NASDAQ:TRIB ) Q4 2023 Earnings Conference Call April 4, 2024 8:00 AM ET Company Participants John Gillard - Chief Executive Officer Des Fitzgerald - Chief Financial Officer Eric Ribner - Investor Relations Conference Call Participants Jim Sidoti - Sidoti & Company Paul Nouri - Noble Operator Greetings! Welcome to the Trinity Biotech's Fourth Quarter and Full Year 2023 Earni...

DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2023 and fiscal year 2023 and key business updates.